Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
BACKGROUND
Ifosfamide encephalopathy is a central nervous system toxicity that occurs in patients treated with ifosfamide. Although it has been reported in European and American patients with various carcinomas, there have been no published reports regarding ifosfamide encephalopathy in Asian patients with bone and soft tissue sarcomas.


METHODS
We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution.


RESULTS
Ifosfamide encephalopathy occurred in 17 of 61 patients (31.2%) to whom ifosfamide was administered and in 29 of 214 ifosfamide treatment courses (13.6%). The most common symptoms of encephalopathy were "confusion," "somnolence," and "mood alteration - agitation." Severe encephalopathy occurred only in patients who received ifosfamide at doses >or=9 g/m(2). A history of cisplatin use was identified as a significant risk factor for the development of ifosfamide-induced encephalopathy.


CONCLUSIONS
Because of the risk of severe encephalopathy, we conclude that patients who have previously received cisplatin or who receive ifosfamide at doses >or=9 g/m(2) require strict monitoring.
Tajino
Takahiro
T
Department of Orthopaedic Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Kikuchi
Shin-ichi
S
Yamada
Hitoshi
H
Takeda
Akira
A
Konno
Shin-ichi
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D002945:Cisplatin / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects*; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D019042:Muscle Neoplasms / Q000188:drug therapy*; D020258:Neurotoxicity Syndromes / Q000453:epidemiology* / Q000209:etiology; D012189:Retrospective Studies; D012307:Risk Factors; D012509:Sarcoma / Q000188:drug therapy*; D055815:Young Adult
D018906:Antineoplastic Agents, Alkylating; D002945:Cisplatin; D007069:Ifosfamide